Resistensi Antiplatelet pada Stroke Iskemik
https://doi.org/10.22146/bns.v18i1.55067 Nurul Rakhmawati(1*), Paryono Paryono(2), Indarwati Setyaningsih(3)
(1)
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(3) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author
Abstract
Aspirin dan clopidogrel merupakan agen antiplatelet yang sering digunakan pada stroke iskemik. Terdapatnya resistensi antiplatelet menjadi penyebab terjadinya stroke rekuren yang telah rutin minum obat. Persentase terjadinya resistensi antiplatelet pada beberapa penelitian sangat bervariasi mulai 3-85% pada aspirin dan 28-44% pada clopidogrel. Mekanisme yang mendasari terjadinya resistensi antiplatelet belum diketahui dengan pasti. Underdiagnosed resistensi antiplatelet pada kasus rekuren stroke iskemik, belum adanya penelitian, dan pembahasan resistensi antiplatelet pada stroke iskemik di Indonesia mendorong penulis untuk melakukan penulisan tinjauan pustaka.
Keywords
Full Text:
PDFReferences
1.Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, 2014. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.
2.Hankey GJ, and Eikelboom, JW. Aspirin resistance. Lancet. 2006;367:606-617.
3.Topçuoglu MA, Arsava EM, and Ay H. Antiplatelet resistance in stroke. Expert Review of Neurotherapeutics. 2011;11(2):251-263.
4.Sweeny JM, Gorog DA, and Fuster V. Antiplatelet drug “resistance”. Part 1: mechanisms and clinical measurements. Nature reviews Cardiology. 2009;6:273-282.
5.Saraf S, Bensalha I and Gorog DA. Antiplatelet Resistance-Does it Exist and How to Measure it? Clinical medicine. Cardiology. 2009;3:77-91.
6.Gurn PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
7.Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. International Journal of Cardiology. 2005;101(1):71-76.
8.Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS, et al. Profile and Prevalence of Aspirin Resistance in Indian Patients with Coronary Artery Disease. Indian Heart J. 2005;57:658-661.
9.Gofir A. Klasifikasi Stroke. Dalam: Manajemen Stroke. Yogyakarta: Pustaka Cendikia Press. 2009:19-43.
10.Tantry US, and Gurbel PA. Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring. Current Pharmaceutical Design. 2013;19:3795-3815.
11.Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis. 2007;5(Suppl. 1):230-237.
12.Departemen Kesehatan Republik Indonesia. Formularium Nasional Edisi Kedua. Jakarta: Depkes RI. 2013:40.
13.Rocca B and Petrucci G. Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. Hindawi Publishing Corporation Thrombosis. 2012;376721:11. Available from: doi:10.1155/2012/376721.
14.Gorelick PB and Farooq MU. Advances in Our Understanding of Resistance to Antiplatelet Agents for Prevention of Ischemic Stroke. Stroke Research & Treatment. 2013;727842:pp.1-7.
15.Thomson RM and Anderson DC. Aspirin and Clopidogrel for Prevention of Ischemic Stroke. Curr Neurol Neurosci Rep. 2013;13(2):327.
16.Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal. 2009;30(4):426-435.
17.Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK. State-of-the-Art:Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. Current Cardiovascular Risk Reports. 2015;9(2):1-19.
18. Prisco D and Marcucci R. Antiplatelet Drug’s Resistance. The Open Atherosclerosis & Thrombosis Journal. 2009;2:24-28.
19.Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. Journal of the American College of Cardiology. 2004;43(6):1127-1129.
20.Casterella PJ. Oral Antiplatelet Therapy Resistance: Definition, diagnosis, and clinical implications. Journal of the American College of Cardiology. 2007:pp.1-7.
21.Xingyang Yi, Jing Lin, Qiang Z, Lang Wu, Wen Cheng, and Chun Wang. Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. Journal cerebrovascular disease. 2016.
22.Wang J, Zhang CJ, Zhang J, He Y, Lee YM, Chen S, et al. Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP). Scientific Reports. 2016;5:7896.
23.Grotemeyer KH, Scharafinski HW, and Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder (A pilot-study including 180 post-stroke patients). Thromb Res. 1993;71:397-403.
24.Krasopoulos G, Brister SJ, Beattie WS, Buchanan R. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. British Medical Journal. 2008;336:195-198.
25.John S & Katzan I. Recurrent Stroke while on Antiplatelet Therapy. Neurol Clin. 2015;33(2):475-489.
26.Kasmeridis C, Apostolakis S, and Lip GYH. Aspirin and aspirin resistance in coronary artery disease. Current Opinion in Pharmacology. 2013;13(2):242-250.
DOI: https://doi.org/10.22146/bns.v18i1.55067
Article Metrics
Abstract views : 2192
| 
views : 12798
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Berkala NeuroSains
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.